Coagulation abnormalities and cardiovascular disease

Current Opinion in Lipidology

Volumn 10, Issue 5, 1999, Pages 443-448

  DeLoughery, Thomas G ^a,b  

^a NRC 3   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; FIBRINOGEN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK; THROMBOCYTE; VEIN THROMBOSIS;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC;

EID: 0033390922     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199910000-00009     Document Type: Review

References (50)

1. 1 Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998; 19:43.
2. 2 Grant PJ. Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk. Prostagland Leukotr Essent Fatty Acids 1997; 57:473-177.
3. 3 Redondo M, Watzke HH, Stucki B, Sulzer I, Demarmels Biasiutti F, Binder BR, et al. Coagulation factors II, V, VII, and X, prothrombin gene mutation 20210G toA transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19:1020-1025.
4. 4 Sanders TAB, DE Grassi T, Miller GJ, Humphries SE. Dietary oleic and palmitic acids and postprandial factor VII in middle-aged men heterozygous and homozygous for factor VII R353Q polymorphism. Am J Clin Nutr 1999; 69:220-225.
5. 5 Pankow JS, Folsom AR, Shahar E, Tsai MY, Jeffery RW, Wing RR. Weight-loss induced changes in plasma factor VII coagulant activity and relation to the factor VII Arg/Gln353 polymorphism in moderately obese adults. Thromb Haemostasis 1998; 79:784-789.
6. 6 Lam KS, Ma OC, Bourke C, Chan LC, Janus ED. Genetic influence of the R/ Q353 genotype on factor VII activity is overwhelmed by environmental factors in Chinese patients with Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1998; 41:760-766.
7. 7 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119:119-127.
8. 8 Doggen CJ, Manger CV, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemostasis 1998; 80:281-285.
9. 9 Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, et al. Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338:79-85.
10. 10 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95:59-62.
11. 11 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/ 5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de l'Infarctus du Mycocarde. Thromb Haemostasis 1995; 74:837-841.
12. 12 Margaglione M, Cappucci G, D'Addedda M, Colaizzo D, Giuliani N, Vecchione G, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562-567. This study highlights the important of the multiple influences that determine plasma levels of PAI-1.
13. 13 Cesari M, Sartori MT, Patrassi GM, Vettore S, Rossi GP. Determinants of plasma levels of plasminogen activator inhibitor-1-a study of normotensive twins. Arterioscler Thromb Vasc Biol 1999; 19:316-320.
14. 453-A polymorphism of the b-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996; 16:386-391. This is a very clear demonstration of how a discreet 'stressor' interacts with a polymorphism in the fibrinogen gene regulates the magnitude in rise of plasma fibrinogen levels.
15. 15 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction - the ECTIM study. Circulation 1996; 93:440-449.
16. 16 Kessler C, Spitzer C, Stauske D, Mende S, Stadlmuller J, Walther R, Rettig R. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemie stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 1997; 17:2880-2884.
17. 17 De Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, et al. - 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18:265-271.
18. 18 Van der Bom JG, de Maat MPM, Bots ML, Haverkate F, De Jong PTVM, Hofman A, et al. Elevated plasma fibrinogen - cause or consequence of cardiovascular disease. Arterioscler Thromb Vasc Biol 1998; 18:621-625.
19. 19 Schmidt H, Schmidt R, Niederkorn K, Horner S, Becsagh P, Reinhart B, et al. Beta-fibrinogen gene polymorphism (C148 to T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol 1998; 18:487-492.
20. 20 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-917.
21. 21 Dacosta A, Tardy-Poncet B, Isaaz K, Cerisier A, Mismetti P, Simitsidis S, et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998; 80:338-340.
22. 22 Mataix J, Quiles JL, Huertas JR, Battino M, Mañas M. Tissue specific interactions of exercise, dietary fatty acids, and vitamin E in lipid peroxidation. Free Radic Biol Med 1998; 24:511-521.
23. 23 Dunn ST, Roberts CR, Schlechter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thrombosis Res 1998; 91:91-99.
24. 24 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817-2821.
25. 25 Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999; 93:2186-2190.
26. 26 Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997; 17:2418-2422.
27. 27 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99:999-1004.
28. 28 Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97:1037-1041.
29. 29 Franco RF, Trip MD, Ten Cate H, Van den Ende A, Prins MH, Kastelein JJP, Reitsma PH. The 20210 G to A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Brit J Haem 1999; 104:50-54.
30. 30 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl J Med 1996; 334:1090-1094.
31. 31 Walter DH, Schächinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350:1217-1219.
32. 32 Garcia-Ribes M, Gonzalez-Lamuno D, Hernandez-Estefania R, Colman T, Pocovi M, Delgado-Rodriguez M, et al. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemostasis 1998; 79:1126-1129.
33. 33 Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, et al. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemostasis 1998; 80:214-217.
34. A polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bb 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96:1424-1431.
35. 35 Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 1999; 33:727-733.
36. A 1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349:385-388.
37. 37 Herrmann SM, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G, et al. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb Haemostasis 1997; 77:1179-1181.
38. 38 Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless W. Prospective study of platelet PLA1/A2 polymorphism, platelet activation, and incidence of coronary heart disease [abstract]. Blood Cells 1998; 92 (Suppl 1):304a.
39. 39 Cennarro A, Casao E, Civeira F, Jensen HK, Faergeman O, Pocoiv M. Pla1/ a2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 143:99-104.
40. 40 Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke CD, Mrozikiewicz PM, et al. A1/A2 polymorphism of gfycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-control study. Lancet 1999; 353:708-712.
41. 41 Mamotte CD, Van Bockxmeer FM, Taylor RR. Pla1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82:13-16.
42. 42 Durante-Mangoni E, Davies GJ, Ahmed N, Ruggiero G, Tuddenham EG. Coronary thrombosis and the platelet glycoprotein IIIA gene PLA2 polymorphism. Thromb Haemost 1998; 80:218-219.
43. 43 Ridker PM, Stampfer MJ. Assessment of genetic markers of coronary thrombosis: promise and precaution. Lancet 1999; 353:687-688. Given the rapid rise in the number of reports that implicate polymorphisms of a variety of genes in promoting risk of cardiovascular disease, this editorial provides a precautionary note and reminds that even with the wonders of molecular biology, basic epidemiological principles still apply.
44. 44 Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92:2382-2388.
45. 45 Di Paola J, Federici A, Mannucci PM, Canciani M, Kritzik M, Kunicki TJ, Nugent D. Low levels of platelet a2b1 integrin correlate with impaired platelet function in a high shear stress system, in patients with type 1 von Willebrand's disease [abstract]. Blood 1998; 92 (Suppl 1):706a.
46. 46 Moshfegh K, Wuillemin WA, Redondo M, Lämmle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353:351-354.
47. 47 Santoso S, Kunicki TJ, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93:2449-3453.
48. 48 Moyer MP, Tracy RP, Tracy PB, Van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18:458-465. This is an important study that ties together lipoprotein metabolism and coagulation.
49. 49 Xu N, Dahlbäck B, Öhlin AK, Nilsson Å. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 1998; 18:33-39.
50. 50 Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103:219-227. A study that suggests HDL may have more than one mechanism for retarding cardiovascular disease.